Emergent BioSolutions signed a five-year agreement with Providence Therapeutics to develop and manufacture the Canadian biotechnology company’s Covid-19 vaccine candidate for about $90 million.

Shared in Mesoblast dropped on the last day of August 2021 after the Melbourne-based biotech was told that the company’s investigational respiratory treatment for Covid-19 needed to undergo another trial in order to receive emergency use authorization (EUA) from U.S. Food and Drug Administration.

The life sciences arm of Boston-based private equity firm Bain Capital successfully raised $1.9 billion to fund future projects that involve medical, drug, and biotechnology projects. 

Lomecel-B – Longeveron’s proprietary off-the-shelf cell therapy for aging frailty – failed the six-minute walk test (6MWT) endpoint of a Phase IIb study, according to a statement published by the Miami-based biotech on Aug. 13.

Gilead Sciences announced on Aug. 9 that the company will require employees and contractors to be fully vaccinated against the novel coronavirus by Oct. 1.

Sanofi agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as the French pharmaceuticals firm bets on next-generation mRNA vaccine technology beyond the Covid-19 pandemic, confirming a Reuters exclusive report.

Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).

Three pharmaceutical and biotechnology companies announced the recent success of their respective funding rounds to support future efforts.

Cell and gene therapies (C&GTs) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C&GTs are continuing to expand, there is a widening gap between the potential of treatment advances and the patient experience. The industry is beginning to acknowledge the problems faced in one of healthcare’s most complex areas for patient experience, according to EmerGENE’s Nareda Mills (Global President Patient Solutions) and Ben Beckley (Global Lead).

BioSpace takes a look at the flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites.